This project will define, via studies performed in rhesus macaques, the most effective and technically simplest methods to administer MVA-based HIV vaccines. The epidermal and dermal layers of the skin, anatomic compartments exceptionally rich in dendritic cells, constitute active immunologic sites that may be easily targeted for noninvasive delivery of vaccines. We will compare the immunogenicity of our MVA-based vaccines when targeted to the epidermis, the dermis or muscle. We will determine the route of MVA vector administration that elicits the best immune responses; determine how route of MVA (and other priming vector) administration affects the function and homing properties (including to mucosal tissues) of vaccine-elicited HIV-specific immune effector cells; exploit MVA's predilection for infection of antigen presenting cells to elicit high-level HIV-antigen-specific immune responses via recruitment of antigen presenting cells (APCs) to the site of virus inoculation; and explore and develop novel needle-free immunization strategies that may be safer, more affordable and more effective in resource-poor countries. This project will: 1) characterize dermabrasion in both rhesus macaques and humans as a simple means by which to access the epidermis, 2) compare the immunogenicity of vaccines deposited to the epidermis, the dermis and muscle of macaques, 3) determine how the inclusion of different DC-recruiting chemokines, either encoded by a recombinant MVA or co-administered with the vaccine inoculation as a recombinant protein, affects MVA immunogenicity, and 4) explore novel methods of inducing mucosal immunity and determine whether the induction of mucosal immunity is primarily determined at the priming or boosting phase of an immunization regimen.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI061728-01
Application #
6844240
Study Section
Special Emphasis Panel (ZAI1-EC-A (M3))
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-09-02
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$528,685
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Petravic, Janka; Vanderford, Thomas H; Silvestri, Guido et al. (2013) Estimating the contribution of the gut to plasma viral load in early SIV infection. Retrovirology 10:105
Garber, David A; O'Mara, Leigh A; Gangadhara, Sailaja et al. (2012) Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86:12605-15
Vanderford, Thomas H; Bleckwehl, Chelsea; Engram, Jessica C et al. (2011) Viral CTL escape mutants are generated in lymph nodes and subsequently become fixed in plasma and rectal mucosa during acute SIV infection of macaques. PLoS Pathog 7:e1002048
Engram, Jessica C; Dunham, Richard M; Makedonas, George et al. (2009) Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol 183:706-17
Chavan, R; Marfatia, K A; An, I C et al. (2006) Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J Virol 80:7676-87
Chahroudi, Ann; Garber, David A; Reeves, Patrick et al. (2006) Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80:8469-81
Chahroudi, Ann; Chavan, Rahul; Kozyr, Natalia et al. (2005) Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79:10397-407